{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000029","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.694683+00:00","generated_at":"2026-06-13T21:03:52.931213+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pacira stockholders approve 3.3M share increase in equity plan; director Gary Pace faces significant withhold vote","bullets":["Stockholders approved Amended 2011 Stock Incentive Plan, adding 3,300,000 new shares for future grants.","Gary Pace elected as Class III director with 16.1M for vs 23.9M withhold (40.3% support).","KPMG ratified as auditor for FY2023 with 41.9M votes for (99.3% of votes cast).","Advisory 'say-on-pay' vote approved with 34.6M for (86.5% of votes cast).","Plan approval vote: 24.1M for, 15.8M against (60.4% for, excluding broker non-votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000029","json":"https://secwatch.observer/filing/0001396814-23-000029.json","markdown":"https://secwatch.observer/filing/0001396814-23-000029.md","text":"https://secwatch.observer/filing/0001396814-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/0001396814-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/pcrx-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:03:52.931213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06d209f7a7f20c322d32f32bf8fb7700991d2458","claim":"Pacira BioSciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain 41,872,540 282,024 12,746","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/0001396814-23-000029-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"9822085cde6c49c3e3a67e4746d6d69dd8d72018","claim":"Pacira BioSciences, Inc. shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 34,600,749 5,320,960 89,006 2,156,595","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/0001396814-23-000029-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"b4c323f6cb3aa3bf5c1bd20c37730f205fec8b02","claim":"Pacira BioSciences, Inc. shareholders approved Approval of the Company's Amended and Restated 2011 Stock Incentive Plan at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 4 — Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan. For Against Abstain Broker Non-Votes 24,138,558 15,817,929 54,228 2,156,595","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/0001396814-23-000029-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"b960193a756e45015bbf2802a4364b5245b34610","claim":"Pacira BioSciences, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 Annual Meeting of Stockholders at the 2023-06-13 meeting.","evidence_excerpt":"Proposal 1 — Election of three Class III directors to hold office until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. Nominee: For Withhold Broker Non-Votes Christopher Christie 39,024,151 986,564 2,156,595 Gary Pace 16,140,036 23,870,679 2,156,595 David Stack 38,008,964 2,001,751 2,156,595","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000029/0001396814-23-000029-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}